Vivimed Labs Limited (VIVIMEDLAB)

Loading page…

Vivimed Labs Limited (VIVIMEDLAB) · mywealthgrid

About

Vivimed Labs Limited operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹2

Market cap

₹47 Cr

P/E

—

P/B

—

Dividend yield

ROE

—

ROCE

-41.8%

Debt / equity

—

OPM

-216.3%

EPS (TTM)

₹-21.2

Book value

₹-25.4

52-week high

—

52-week low

—

1,837 historical price candles were omitted because the exchange source has not been verified.

₹5.7+2.9%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -149.1% (3-yr avg)
−Revenue shrank over the last 5 years (-39.5% a year)
−Weak interest coverage of -41×
−Low promoter holding of 7.6%
−Promoter holding fell 13.4 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

33/100

Business quality: 0
Growth: 0
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,356	1,470	1,186	1,059	861	237	187	149	116	70
COGS	—	—	480	463	355	153	272	71	60	74
Gross profit	—	—	706	596	507	84	-84	78	56	-4
	—	—	494	588	483	92	103	111	69	148
	—	—	212	8	24	-8	-187	-33	-13	-151
OPM %	—	—	17.9%	0.8%	2.8%	-3.4%	-100.1%	-22.4%	-10.8%	-216.3%
Depreciation	—	—	56	67	55	18	108	20	20	26
Interest	—	—	79	59	54	40	36	2	3	4
	—	—	11	8	10	1	1	10	4	6
Profit before tax	100	296	88	-109	-76	-65	-331	-46	-31	-175
Tax	—	—	10	-0	2	3	-2	-0	0	0
Tax %	—	—	11%	-0.3%	2.7%	4.4%	-0.6%	-0.8%	0.4%	0.1%
	84	222	78	-109	-78	-68	-329	-45	-32	-175
PAT margin %	6.2%	15.1%	6.6%	-10.3%	-9%	-28.5%	-175.6%	-30.5%	-27.1%	-250.6%
EPS (₹)	—	—	18.4	-13.2	-18.8	-8.2	-39.6	-5.5	-3.9	-21.2
EPS adjusted (₹)	10.3	27.4	—	-13.2	-9.4	-8.2	-39.6	-5.5	-3.8	-21.2
	—	—	2.2%	—	—	—	—	—	—	—
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16	16	17	17	17	17	17	17	17	17
Reserves	505	708	—	818	415	348	23	-22	-52	-227
Minority interest	—	—	—	—	0	0	—	—	—	0
	665	829	—	889	326	359	379	377	847	397
	857	513	—	486	532	543	570	579	109	567
Total equity & liabilities	2,044	2,066	—	2,210	1,289	1,266	988	951	921	753
	814	879	965	1,045	502	520	278	418	408	386
CWIP	94	76	—	89	60	40	21	21	17	18
Investments	3	3	—	86	199	199	199	169	169	181
	1,133	1,107	—	990	529	507	491	344	328	170
Total assets	2,044	2,066	—	2,210	1,289	1,266	988	951	921	753

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs.

Source XBRL ↗

Latest reported period · 31 Mar 2024 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities
Pharma Business	143.17	-27.33	—	0
Speciality Chemicals Business	5.9	-26.03	—	0

SegmentFigure

Pharma Business · revenue

₹ crore by fiscal year

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	59.5%	56.3%	58.8%	35.3%	-45.1%	52%	48.5%	-5.4%
EBITDA margin %	17.9%	0.8%	2.8%	-3.4%	-100.1%	-22.4%	-10.8%	-216.3%
EBIT margin %	13.1%	-5.6%	-3.7%	-11.1%	-158.1%	-35.8%	-28.2%	-253.5%
PAT margin %	6.6%	-10.3%	-9%	-28.5%	-175.6%	-30.5%	-27.1%	-250.6%
Working capital
Receivable days	—	86	46	134	150	203	233	236
Inventory days	—	396	263	573	107	327	358	63
Payable days	—	179	35	100	93	225	240	263
NWC days	—	303	274	607	164	305	351	36
Leverage
Current ratio	—	1.28	1.55	1.36	0.78	0.83	0.8	0.37
Debt to EBITDA	—	109.65	13.69	—	—	—	—	—
Debt to equity	—	1.07	0.75	0.99	9.6	-69.03	-24.07	-1.89
Interest coverage	2.1	-0.9	-0.4	-0.6	-8.2	-17.9	-9.6	-41
Asset turnover	—	0.48	0.67	0.19	0.19	0.16	0.13	0.09
Return ratios
Return on assets %	—	-4.9%	-6%	-5.3%	-33.2%	-4.8%	-3.4%	-23.3%
Return on capital employed %	—	-3.5%	-1.8%	-2.7%	-40.5%	-7.9%	-5.4%	-41.8%
Return on equity %	—	-13.1%	-18%	-18.6%	-833.4%	832.4%	89.6%	83.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	7.77%	7.77%	7.77%	7.57%
	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.12%	0.12%	0.12%
	77.42%	77.42%	77.42%	77.42%	77.42%	77.42%	77.42%	77.42%	90.59%	90.47%	90.47%	90.67%
No. of shareholders	—	—	—	—	—	—	—	—	—	48,925	49,221	47,492

Promoter holding down 13.37 percentage points since Jun 2023.

13 deals · 20 Jan 2022 – 10 Feb 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
10 Feb 2026	KRONE FINSTOCK PRIVATE LIMITED	Bulk	NSE	Sell	5,81,010	₹7.41	₹0.43 Cr
10 Feb 2026	KRONE FINSTOCK PRIVATE LIMITED	Bulk	NSE	Buy	6,010	₹7.68	₹0.00 Cr
20 Jan 2026	KAMAL JEET GUPTA	Bulk	NSE	Buy	4,30,000	₹8.17	₹0.35 Cr
20 Jan 2026	KAMAL JEET GUPTA	Bulk	NSE	Sell	1,30,000	₹7.82	₹0.10 Cr
6 Jan 2026	NEO APEX VENTURE LLP	Bulk	NSE	Buy	10,48,963	₹12.25	₹1.28 Cr
6 Jan 2026	MERU INVESTMENTS	Bulk	NSE	Buy	4,50,000	₹12.25	₹0.55 Cr
6 Jan 2026	NEO APEX VENTURE LLP	Bulk	NSE	Sell	2,98,970	₹12.25	₹0.37 Cr
3 Apr 2023	A AND S TRADELINK	Bulk	NSE	Buy	7,12,573	₹6.42	₹0.46 Cr
21 Jun 2022	LUHARUKA MEDIA & INFRA LTD	Bulk	NSE	Sell	5,51,627	₹7.66	₹0.42 Cr
29 Mar 2022	KRONE FINSTOCK PRIVATE LIMITED	Bulk	NSE	Sell	4,31,000	₹15.15	₹0.65 Cr

1–10 of 13

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Manohar Rao VaralwarExecutive Director-Chairperson
Mr. Santosh VaralwarExecutive Director-MD
Mr. Sandeep VaralwarExecutive Director
Ms. Aparna BidarkarNon-Executive - Independent Director
Mr. Jarugula Siva PrasadNon-Executive - Independent Director
Ms. Subbarathnamma PalepuNon-Executive - Independent Director
Yugandhar KopparthiCompany Secretary and Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Vivimed Labs Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

9

Dividend dividend19 Sept 2018 · ex-date₹0.4
Dividend dividend21 Sept 2017 · ex-date₹0.4
Dividend dividend24 Sept 2014 · ex-date₹3
Dividend dividend24 Sept 2013 · ex-date₹3
Final dividend21 Sept 2012 · ex-date₹3
Final dividend26 Sept 2011 · ex-date₹2
Dividend dividend9 Sept 2010 · ex-date₹1.5
Dividend dividend24 Sept 2009 · ex-date₹1.5
Dividend dividend22 Sept 2008 · ex-date₹1

1

Board meeting to consider results17 Jul 2026

1

Face value ₹10 → ₹26 Apr 2016 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

7 announcementsExport CSV

8 Sept 2026, 4:31 pmCompany Update

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

Intimation of meeting of Committee of Creditors PDF

17 Aug 2026, 4:40 pmCompany Update

Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

Intimation of meeting of Committee of Creditors PDF

22 Jul 2026, 4:57 pmCompany Update

Re- Lodgement Of Transfer Requests

General PDF

22 Jul 2026, 4:54 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

17 Jul 2026, 6:23 pmResult

Results As On 31.3.2026

Financial Results PDF

14 Jul 2026, 7:56 pmBoard Meeting

Board Meeting Intimation for Quarter & Year End Results 31.3.2026

Exchange filing PDF

10 Jul 2026, 3:44 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
8 Sept 2026, 4:31 pm	Company Update Intimation of meeting of Committee of Creditors	Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors	PDF
17 Aug 2026, 4:40 pm	Company Update Intimation of meeting of Committee of Creditors	Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors

Loading announcements…

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	59.5%	56.3%	58.8%	35.3%	-45.1%	52%	48.5%	-5.4%
EBITDA margin %	17.9%	0.8%	2.8%	-3.4%	-100.1%	-22.4%	-10.8%	-216.3%
EBIT margin %	13.1%	-5.6%	-3.7%	-11.1%	-158.1%	-35.8%	-28.2%	-253.5%
PAT margin %	6.6%	-10.3%	-9%	-28.5%	-175.6%	-30.5%	-27.1%	-250.6%
Working capital
Receivable days	—	86	46	134	150	203	233	236
Inventory days	—	396	263	573	107	327	358	63
Payable days	—	179	35	100	93	225	240	263
NWC days	—	303	274	607	164	305	351	36
Leverage
Current ratio	—	1.28	1.55	1.36	0.78	0.83	0.8	0.37
Debt to EBITDA	—	109.65	13.69	—	—	—	—	—
Debt to equity	—	1.07	0.75	0.99	9.6	-69.03	-24.07	-1.89
Interest coverage	2.1	-0.9	-0.4	-0.6	-8.2	-17.9	-9.6	-41
Asset turnover	—	0.48	0.67	0.19	0.19	0.16	0.13	0.09
Return ratios
Return on assets %	—	-4.9%	-6%	-5.3%	-33.2%	-4.8%	-3.4%	-23.3%
Return on capital employed %	—	-3.5%	-1.8%	-2.7%	-40.5%	-7.9%	-5.4%	-41.8%
Return on equity %	—	-13.1%	-18%	-18.6%	-833.4%	832.4%	89.6%	83.3%

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	58	21	80	567	-658	14	-24	-11	8
	-68	-164	-196	404	523	-1	28	5	-1
	35	186	72	-1,015	-10	-16	-6	5	-6
Net cash flow	25	44	-44	-44	-146	-3	-2	-1	1
Free cash flow	—	—	-33	567	-658	13	-24	-15	8
CFO / Operating profit %	—	10.1%	981.1%	—	—	—	—	—	—

Vivimed Labs Limited

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Pharma Business · revenue

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Dividends9

Board meetings1

Stock splits1

Announcements

Dividends9

Board meetings1

Stock splits1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Segment results

Pharma Business · revenue

Cash flow

Compounded returns

Compounded sales growth

Return on equity

9

1

1

9

1

1